82P.F Pacira BioSciences Inc

Healthcare Pharmaceuticals Frankfurt Exchange
32.40 EUR
Close of Nov 12, 2026
15.40 32.60
Market cap
EUR 1.29B
P/E
40.5x
P/B
2.02x
ROE
6.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 82P.F undervalued?

Graham number
Price32.40
Graham value16.97
Premium90.9%

82P.F trades 90.9% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pacira BioSciences Inc fundamental analysis

No fundamental analysis for Pacira BioSciences Inc yet.

Pacira BioSciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pacira BioSciences Inc

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a …

Full company profile